The EUA potential in US & Worldwide while on the path to BLA are being completely overlooked. BARDA & NIH cooperation is a great tell of what's coming, and it just so happens that this data is being supported by The Mayo Clinic among other highly prestigious Hospitals.
In addition to Covid, I think the ability to open up Car-T with better efficacy then current s.o.c. is being overlooked. Novartis with Kymriah, Bristol Myers Squibb's latest approved Breyanzi, and of course Kite/Gilead's Yescarta all can use Lenzilumab's ability to stop Cytokine Storm. I am anxiously awaiting the Phase I portion of Zuma-19 as that could provide data for the others to look to HGEN. Best part of Zuma-19 is that a Phase III may not even be required.
There is allot to be excited about here.